Strategic Funding to advance Drug Candidate
Jan 14 2021 Read 170 Times
Biologics manufacturer eleva GmbH has secured up to EUR 60 million in funding from Zukunftsfonds Heilbronn (ZFHN). The funds will help advance one of its drug candidates, CPV-101, to stages that will facilitate further investment from venture capitalists and/or pharmaceutical companies. The company also announced the addition of Dr. Ralf Smit to its Executive Board.
The Freiburg-based company developed its moss-based platform to produce biologics like antibodies, replacement enzymes, or fusion toxins. The funding from ZFHN, an investor in local start-ups, will is now providing help take CPV-101, a potentially game-changing complement regulator, to more advanced clinical stages and further investments This will enable additional investment on the path to approval.
Codoxo names Rena Bielinski as Vice President of Customer Success and Scott Byerley as Vice President of Sales thetelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thetelegraph.com Daily Mail and Mail on Sunday newspapers.
(2)
Glow LifeTech has the exclusive rights for MyCell Technology in the United States, Canada and Mexico for one of the primary ingredients used in ArtemiC, a COVID-19 Treatment Candidate with successful Phase II Clinical Results
The formulation statistically significantly improved the clinical recovery of COVID-19 patients in the treatment group in comparison with placebo and 100% of the patients in the treatment group fully recovered within 15 days
Positive results from a phase II double blind randomized controlled clinical trial show the MyCell Technology ArtemiC formulation, successfully met the primary and secondary endpoints for safety and efficacy
1
ArtemiC is a natural anti-inflammatory formulation by Glow partner Swiss PharmaCan and MGC Pharma, intended to suppress cytokine storm and clinical deterioration prevention to support the recovery of COVID-19 patients
Jan 14 2021 Read 266 Times
University of Birmingham (UK) scientists have shown that a novel low molecular weight dextran-sulphate, ILB® could play a key role in treating open angle glaucoma (OAG), a neurodegenerative disease, affecting over 70 million people worldwide, by lowering increased intraocular pressure (IOP) within the eye’s main fluid drainage site.,
OAG develops slowly over many years, leading to excessive matrix deposition (fibrosis), which in turn can lead to increased intraocular pressure (IOP), causing damage to the optic nerve and blindness.
The research has shown that that ILB can normalise matrix deposition inside the eye in a pre-clinical model used to mimic these aspects of human glaucoma, paving the way for new anti-fibrotic therapies to be developed for the disease.